Systematic Reviews
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. May 15, 2024; 16(5): 2141-2158
Published online May 15, 2024. doi: 10.4251/wjgo.v16.i5.2141
Table 1 Overview of articles eligible for data extraction with methodological details
Ref.
Type of article
Time of inclusion
% (SRC/total study population)
Database
Compared to
Tawadros et al[13], 2015Retrospective cohort study2004-2010< 40 yr: 3%, > 40 yr: 0.87% (NA)SEERMA and OA of the rectum
Song et al[25], 2017Retrospective cohort study (pT1 cancer)1988-201162/21463 (0.3%)SEERMA and OA
Wei et al[41], 2016Retrospective case series (SRC component)11/2008-01/201539 group A, 22 group BNAGroup A (> 50% SRC) and group B (< 50% SRC, but with SRC component)
Wu et al[9], 2018Retrospective cohort study1988-20124402 colon + 853 rectum/24171 overall SRCSEEROther SRCC locations (bladder, breast, esophagus, gallbladder, lung, pancreas, small intestine)
Hartmann et al[16], 2013Retrospective case series2002-201253/4760 (1.1%)NA40 (75%) mucin-rich SRCC vs 13 (25%) mucin-poor SRCC and 23 (43%) MSI-H SRCC vs 30 (57%) MSS SRCC
Pande et al[54], 2008Retrospective cohort study (SRC component < 50%)01/2002-05/200639/753 (5.1%)NAMA, CMA, > 50% SRRC, < 50% SRC component, OA in a random sample size of 100 patients
van Oudheusden et al[59], 2015Retrospective cohort study04/2005-12/201320/351 (5.7%): CRS + HIPEC in 16/20 (80%)NACRS + HIPEC in SRCC vs CRS + HIPEC in other differentiation (252/331)
Wu et al[10], 2019Retrospective cohort study2004-20154140/399791 (1.0%)SEERMA and NMA
Hyngstrom et al[19], 2012Retrospective cohort study1998-20022260/244794 (1%)NAMA and OA
Hugen et al[17], 2015Retrospective cohort study1989-20101972/196757 (1.0%)NAMA and OA
Shi et al[61], 2019Retrospective cohort study2010-20141932/173460SEERNon-SRCC
Kang et al[12], 2005Retrospective cohort study1991-20001522/164628 (0.9%)NAMA and OA
Ciarrocchi[4], 2014Retrospective cohort study2004-20091484NARectal SRCC vs non-rectal colonic SRCC
Huang et al[26], 2016Retrospective cohort study (<35/>35 y with SRCC)01/1988-12/2011NASEERNA
Ling et al[50], 2017Retrospective cohort study1988-2011622/69543 (0.9%)NAMA and OA of the rectum
Simkens et al[38], 2016Retrospective cohort study01/2005-12/2014385/5516 (7%)NAMA and OA with peritoneal metastases
Razenberg et al[62], 2015Retrospective cohort study (peritoneal metastases +)01/2005-12/2012311/4277 (7%)NAMA and OA with peritoneal metastases
Wu et al[11], 2017Retrospective case series1988-2012292 (stage II and III rectal SRCC)NANA
Thota et al[30], 2014Retrospective cohort study01/1995-12/2008206/36260 (0.6%)VACCRMA and NMA
Tamhankar et al[51], 2016Retrospective case series01/2011-12/2013170/1487 (11.4%)NANA
Nitsche et al[33], 2013Retrospective cohort study1998-2012160/28056 (0.6%)SEERMA and OA
Fu et al[58], 2016Retrospective cohort study1998-201094/3568 (2.6%)NAResectable metastatic SRRC vs resectable metastatic non-SRCC
Kakar and Smyrk[44], 2005Retrospective case series1985-200072NANA
Yun et al[63], 2017Retrospective cohort study (+ propensity score matching)09/1994-12/201371/12631 (0.56%)NAOA
Sung et al[21], 2008Retrospective cohort study01/1995-12/200665NAMA
Chen et al[6], 2004Retrospective cohort study01/1979-07/200161/2619 (2.3%)NAMA and NMA of the rectum
Wang et al[43], 2016Retrospective case series09/2008-07/201459/6625 (0.89%)NANA
Nissan et al[18], 1999Retrospective case matched study/cohort study1986-199740/5350 (0.7%)NACG/non-signet-ring CRC
Liang et al[31], 2018Retrospective case series01/1990-12/201037/2643 (1.4%)NANA
Korphaisarn et al[46], 2019Retrospective cohort study (metastatic CRC)03/1994-11/201535/665 (5.3%), 28(4.2%) SRC componentNAOA with SRC component and OA
Lee et al[52], 2007Retrospective cohort study10/1996-12/200535/5022 (0.7%)NAMA and poorly differentiated OA
Bittorf et al[8], 2004Retrospective cohort study01/1978-12/199934/4458 (0.8%)NANon-SRCC
Messerini et al[32], 1995Retrospective case series01/1985-12/199334/2995 (1.1%)NANA
Bademci et al[28], 2019Retrospective case series2009-201834/3180 (1.06%)NANA
Chua et al[53], 2009Retrospective case series (peritoneal carcinomatosis)01/1997-12/200833NANA
Kakar et al[45], 2012Retrospective cohort studyNA33NAMA and OA
Barresi et al[27], 2016Retrospective case series2003-201432/3248NANA
Chew et al[22], 2010Retrospective cohort study01/1999-12-200530/2764 (1.1%)NAMA and OA
Nitsche et al[1], 2016Retrospective cohort study01/1982-10/201230/3479 (0.9%)NAMA and OA
Anthony et al[7], 1996Retrospective case series09/1971-12/199329/3690 (0.8%)NANA
Song et al[64], 2009Retrospective cohort study08/1994-03/200725/2079 (1.2%)NAMA and NMA
Belli et al[20], 2014Retrospective case series03/2007-06/201322/842 (2.6%)NANA
Zhang et al[65], 2020Retrospective cohort study2006-201321 vs 90NAMA
Wang et al[39], 2019Retrospective cohort study2004-201321/90 (SRC/SRC + MAC)NAMA
Song et al[66], 2019Retrospective cohort study2000-201020/299NAPredominant SRCC (> 50% SRCC) vs mixed SRC vs cluster predominant vs strip predominant
Mizushima et al[36], 2010Retrospective cohort study1993-200719/5884 (0.32%)NAWell or moderately differentiated OA and poorly differentiated MA
Foda et al[42], 2018Retrospective cohort study01/2007-12/201119/150 (12.6%)NAMA, OA, OA with mucinous component
Lee et al[29], 2015Retrospective case matched study01/2003-12/201115 vs 75 NMANANMA
Imai et al[67], 2013Retrospective cohort study04/1998-03/200015/250 (6%)NAWell or moderately differentiated OA, poorly differentiated OA and MA
Psathakis et al[15], 1999Retrospective case matched study/cohort study01/1979-12/199714/1600 (0.88%)NANon-SRCC
Pozos-Ochoa et al[37], 2018Retrospective cohort study1995-201512NAMA with SRC component
Sasaki et al[14], 1998Retrospective cohort study01/1963-12/199611/1595 (0.7%)NAMucinous adenocarcinoma (KRAS mutation screening in 30 control advanced colorectal carcinomas)
Ooi et al[23], 2001Retrospective case series1989-19999/3000 (0.3%)NANA
Secco et al[68], 1994Retrospective cohort study01/1979-12/19864/352 (1.1%)NAMA and OA
SRC: Signet-ring cell; SRCC: Signet-ring cell cancer; MA: Mucinous adenocarcinoma; OA: Ordinary/conventional adenocarcinoma; NMA: Non-mucinous adenocarcinoma; CMA: Component of mucinous adenocarcinoma; CRS: Cytoreductive surgery; HIPEC: Hyperthermic intraperitoneal chemotherapy; MSI-H: Microsatellite instability-high; MSS: Microsatellite stable; NA: Not applicable; CG: Control group; SEER: Surveillance, Epidemiology and End Results program database; VACCR: Veterans Affairs Central Cancer Registry; CRC: Colorectal cancer; MAC: Mucinous adenocarcinoma.